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The cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is involved in 
the pathogenesis of chronic inflammatory diseases such as multiple sclerosis. However, 
the environmental cues promoting differentiation of GM-CSF producing T  cells are 
unclear. Herein, we performed a broad experimental screening of cytokines and data-
driven analysis assessing their ability to induce human GM-CSF+ CD4+ T cells and their 
subpopulations. TGF-β was discovered to induce GM-CSF production independently of 
proliferation and IL-2 signaling including STAT5. In contrast, IL-6 and IL-23 decreased 
GM-CSF production. On the population level, GM-CSF induction was highly correlated 
with expression of FOXP3 across cytokine stimulations but not with that of IL-17. 
However, on single-cell level GM-CSF and IFN-γ expression were most correlated, 
independently of the cytokine environment. Importantly, under low sodium conditions 
in the medium or upon stimulation with plate-bound instead of bead-bound anti-CD3 
and anti-CD28 antibodies, the effects of TGF-β on GM-CSF, but not on FOXP3, were 
reversed. Our analysis indicates a novel role for TGF-β in generating GM-CSF+ subsets 
of human CD4+ T cells. These results are important for understanding of autoimmune 
disease and therapeutic considerations.
Keywords: human cD4+ T cells, differentiation, gM-csF, TgF-β, autoimmune diseases, multiple sclerosis, 
multivariate analysis, sodium
inTrODUcTiOn
CD4+ T cells are central in directing immune responses and have been implicated in numerous 
diseases such as chronic inflammation, cancer, and neurodegenerative diseases. CD4+ T cells can be 
classified as effector T helper (Th) cells and immunosuppressive regulatory T cells (Treg). Th cells can 
be further divided into the major subsets Th1, Th2, and Th17 cells, based on their cytokine profile such 
as expression of IFN-γ, IL-4, and IL-17 that is driven largely by expression of the lineage-defining 
transcription factors T-bet, GATA-3, and RORγt, respectively (1). The most important Treg subset, 
comprised of thymus-derived and peripherally induced Tregs, is characterized by expression of the 
lineage-defining transcription factor FOXP3 (2). However, recent investigations revealed numerous 
subsets as well as plasticity in the CD4+ T cell population beyond the classical distinction between 
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Th1, Th2, Th17, and Treg (3, 4). For example, Th9, Th22, Tfh, Tfr have 
been described as additional subpopulations (1).
Another emerging Th cell subset is defined by the produc-
tion of granulocyte-macrophage colony-stimulating factor 
(GM-CSF). So far no lineage-defining transcription factor has 
been identified for this subpopulation. In CD4+ T cells GM-CSF 
can be co-expressed with other lineage-defining cytokines such 
as IFN-γ, but GM-CSF single-positive cells have also been 
identified (5). The importance of GM-CSF in inflammatory 
disorders is illustrated by the fact that GM-CSF−/− mice are 
completely resistant to experimental autoimmune encephalo-
myelitis (EAE), an animal model for multiple sclerosis (MS) 
(6, 7). GM-CSF produced by auto-reactive T cells is necessary 
for the onset of EAE (8) unlike IFN-γ and IL-17 (7, 8). In human 
cerebrospinal fluid, the fraction of GM-CSF+ and IFN-γ+ cells 
within CD4+ T cells was elevated in MS patients compared to 
controls whereas the fraction of IL-17+ cells was not significantly 
different (5). In peripheral blood, the fraction of GM-CSF+ and 
IFN-γ+ cells within CD4+ T cells was elevated in MS patients 
compared to controls in one study (9) but not in another (5). 
Interestingly, myelin-reactive T cells – present in MS patients 
and healthy donors with comparable frequencies – have been 
determined by single-cell cloning to produce more IFN-γ, IL-17, 
and GM-CSF and less IL-10 in MS patients compared to healthy 
controls (10).
It has been proposed from cell transfer experiments in EAE that 
Th17 cells have “non-pathogenic Th17” and “pathogenic Th17” sub-
classes and that the latter expresses GM-CSF (11–13). However, 
the factors inducing pathogenic CD4+ T cells and the markers 
defining them on the single-cell level are incompletely under-
stood. IL-1β, IL-23, TGF-β3, and NaCl have been proposed as 
induction factors of murine pathogenic Th17 cells (11–16). Notably 
IL-23 – a cytokine not produced by T cells – has a  well-known 
role in inducing autoimmune disease, a fact that has been linked 
to its effect on Th17 cells. Under Th17-polarizing conditions, IL-1β 
and IL-23 induce GM-CSF+IL-17+ double-positive murine cells 
(14). Th17 cells generated under addition of TGF-β3 or elevated 
NaCl concentrations displayed enhanced expression of Csf2 (the 
gene encoding for GM-CSF) on the population level but have not 
been studied at single-cell resolution (11, 13). Another study on 
the contrary found that neither addition of TGF-β1 nor TGF-β3 
rendered murine Th17 cells pathogenic, possibly due to insufficient 
GM-CSF production (17).
Together, the identity of pathogenic CD4+ T cells remains 
obscure, while the importance of T cell-produced GM-CSF is 
undisputed. Pathogenicity cannot be tested in humans and it 
appears that there are differences in human compared to murine 
GM-CSF+ T cells. For example, on the level of single CD4+ T cells, 
IL-17 and GM-CSF can be co-expressed in murine cells (14), 
whereas their expression was mutually exclusive in human cells 
(5). Regarding factors inducing GM-CSF in human CD4+ T cells, 
TGF-β1 or TGF-β3 was found to decrease GM-CSF production 
in one study (9), while TGF-β1 had no effect in another (5). IL-23 
and IL-6 did not augment GM-CSF (5, 9), whereas IL-2 or IL-7 
signaling induced GM-CSF expression in a STAT5-dependent 
manner and IL-1β induced IFN-γ+ GM-CSF+ double-positive 
cells (5, 9).
Together, the results of the above studies support a role of 
GM-CSF+ CD4+ T cells in MS but despite their importance in 
disease, the differentiation factors and characteristics of human 
GM-CSF+ CD4+ T cells are poorly defined and seem to be differ-
ent from the ones in mouse. Here, we screened several cytokines 
in various combinations for their ability to induce GM-CSF+ cells 
from human naïve CD4+ T cells. We found that TGF-β was the 
most potent inducer of GM-CSF+ CD4+ T cells, which was also 
dependent on the mode of T cell activation and independent of 
IL-2 signaling. In contrast, IL-23 and IL-6 inhibited GM-CSF 
production. GM-CSF+ cells comprised several subpopulations 
and were induced under similar conditions as FOXP3+ cells on 
the population level while on single-cell level, IFN-γ was most 
strongly correlated with GM-CSF. Notably, under low sodium 
conditions, the effects of TGF-β on GM-CSF induction were 
reversed. Our results shed light on the cytokine, medium, and 
stimulation conditions required to induce human GM-CSF+ 
T cells and their phenotype regarding subpopulations, which may 
contribute to the understanding of their role in human autoim-
mune disease in the future.
MaTerials anD MeThODs
cell isolation
Human peripheral blood mononuclear cells (PBMCs) were iso-
lated using Ficoll-Paque gradient centrifugation. In brief, buffy 
coats diluted in PBS were overlaid on Ficoll-Paque and centri-
fuged at 1200 × g for 20 min without break and the PBMC ring 
was collected. Cells were washed with PBS (450 × g, 10 min) and 
monocytes depleted by adherence to plastic culture flasks. Human 
naïve CD4+ T cells were isolated using the human naive CD4+ 
T cell isolation kit (Miltenyi) according to the manufacturer’s 
instructions. The purity of naïve CD4+ T cells was controlled by 
flow cytometry and was above 94%.
In Vitro T cell Differentiation
Human naïve CD4+ T cells were cultured in 96-well round bot-
tom plates in serum-free X-VIVO 15 medium (Lonza) with a 
final sodium concentration of 145.8 mM (by addition of 30 mM 
NaCl) and activated using Dynabeads Human T-Activator 
anti-CD3-, anti-CD28-coated beads (Invitrogen) at bead:cell 
ratio of 1:1 in the presence of the specified cytokines and 10 µg/
ml each anti-IFN-γ (RnD systems) and anti-IL-4 (RnD systems) 
blocking antibodies for 5  days unless otherwise stated. The 
sodium concentration in blood plasma is (135 to) 145 mM Na+. 
Addition of 30 mM NaCl to X-VIVO 15 medium resembles this 
physiological Na+ concentration (here termed “physiologic” 
sodium conditions) and X-VIVO 15 medium supplemented 
in this way has been used by others to culture CD4+ T cells 
(18, 19). In some experiments (termed “low sodium” conditions), 
no additional NaCl was added to the X-VIVO 15 medium (which 
contains 115.8  mM total sodium). In some experiments, cells 
were activated with 5 µg/ml plate-bound (pb) anti-CD3 (clone 
OKT3; Biolegend, LEAF grade) and 1 µg/ml soluble anti-CD28 
antibody (clone CD28.2; Biolegend, LEAF grade). Cytokines 
(all from RnD Systems) were used at the following concentrations 
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unless otherwise stated: IL-1β (12.5  ng/ml), IL-6 (25  ng/ml), 
IL-21 (25 ng/ml, Life technologies), IL-23 (25 ng/ml), IL-2 (100 
IU/ml), IL-10 (5 or 25 ng/ml), TGF-β1 (5 ng/ml), and TGF-β3 
(5  ng/ml). Where indicated, STAT5 inhibitor (N′-((4-Oxo-
4H-chromen-3-yl)methylene)nicotinohydrazide, CAS No.: 
285986-31-4, Merck Millipore/Calbiochem) at 200 µM or anti-
IL-2-blocking antibody (BD Pharmingen, clone: MQ1-17H12, 
no azide/low endotoxin) at 5 µg/ml or respective isotype control 
antibody was added.
Flow cytometry
Naïve CD4+ T cell purity was verified by surface staining 
using anti-CD45RA-FITC (Miltenyi, Clone: T6D11) and 
anti-CD4-APC (eBioscience, Clone: OKT4) antibodies followed 
by flow cytometry.
Viability staining and proliferation staining were done 
using Fixable Viability Dye eFluor 780 (eBioscience) and 
Cell Proliferation Dye eFluor 450 (eBioscience), respectively, 
according to the manufacturer’s instructions.
Prior to all intracellular stainings, cells were restimulated for 
5 h using 10 ng/ml phorbol 12-myristate 13-acetate (PMA) and 
375  ng/ml ionomycin (Iono) in the presence of 1× GolgiPlug 
containing Brefeldin A (BFA; BD Biosciences) to block protein 
secretion. Then, cells were resuspended thoroughly and mag-
netic anti-CD3/anti-CD28-coated beads were removed on a 
magnet. Intracellular stainings were performed using the FOXP3 
Transcription Factor Staining Buffer Set (eBioscience) according 
to the manufacturer’s instructions.
The following antibodies (all against the human proteins) were 
used: GM-CSF-APC (Miltenyi, clone: BVD2-21C11), GM-CSF-
PE-CF594 (BD Biosciences, clone BVD2-21C11), FOXP3-FITC 
(eBioscience, clone: 236A/E7), FOXP3-eFluor450 (eBioscience, 
clone: 236A/E7), FOXP3-APC (eBioscience, clone: 236A/E7), 
IFN-γ-FITC (eBioscience, clone: 4S.B3), IFN-γ-PE-Vio770 
(eBioscience, clone: 45-15), IL-17A-PE (eBioscience, clone: 
Bio64DEC17), CD25-PE (Miltenyi, clone: 4E3), IL-2-PE-CF594 
(BD Biosciences, clone: 5344.111), CD4-PE-CF594 (BD 
Biosciences, clone: RPA-T4). The following antibodies were used 
for isotype control staining: Mouse IgG1κ Isotype Control-FITC 
(eBioscience, clone: P3.6.2.8.1), Mouse IgG1κ Isotype Control-PE 
(eBioscience, clone: P3.6.2.8.1), Mouse IgG1κ Isotype Control-
PE-Vio770 (Miltenyi, clone: IS5-21F5), Mouse IgG1κ Isotype 
Control-PE-CF594 (BD Biosciences, clone: X40), Mouse IgG1κ 
Isotype Control-APC (eBioscience, clone: P3.6.2.8.1), Rat IgG2aκ 
Isotype Control-PE-CF594 (BD Biosciences, clone: R35-95), Rat 
IgG2aκ Isotype Control-APC (eBioscience, clone: eBR2a).
Flow Cytometry recording was performed on a CyAn ADP 
9-Color Analyzer (Beckman Coulter), and compensation settings 
were created automatically with the CyAn software (Summit) 
using single stained compensation beads (BD CompBeads, BD 
Biosciences) containing both positive and negative populations.
Flow cytometry data analysis was performed using the R 
programming language for statistical computing including the 
flowCore (20), flowStats (21) R packages, or with the FlowJo 
software (Tree Star). Gating strategy involved the following 
sequential steps: gating on lymphocytes based on forward and side 
scatter, doublet-exclusion based on pulse width versus forward 
scatter area, gating on live cells (Fixable Viability Dye-eFluor780 
negative population), and in case when CD4 staining was used 
gating on CD4+ population.
enzyme-linked immunosorbent  
assay (elisa)
Sandwich ELISA for human GM-CSF was performed with the 
Human GM-CSF Mini ABTS ELISA Development Kit (Peprotech) 
along with ABTS substrate (Sigma-Aldrich)  according to the 
manufacturer’s instructions.
statistical analysis
The R programming language was used for statistical analysis. 
When data were not normally distributed according to Shapiro–
Wilk test, the non-parametric Wilcoxon signed-rank test was used 
paired within each donor to determine statistical significance for 
comparing groups. Significance is presented as p-value.
Model selection Using lassO regression 
for regularization
Linear regression with shrinkage (least absolute shrinkage and 
selection operator, LASSO) was carried out using the glmnet (22) 
R package. The target variable was the difference in the GM-CSF+ 
cell fraction within live cells between the cytokine-treated sample 
and the control (activation without cytokines) for every given 
donor. The full set of predictors (prior selection) were defined as 
(i) cytokines that were applied in the stimulation experiments, 
(ii) interactions between all pairs of cytokines in the stimulation 
experiments, and (iii) time. The predictors were standardized 
and transformed in the following way: the concentration values 
of each cytokine (i) and time (iii) were all normalized between 
values 0 and 1 in order to prevent detection of differential effects 
between predictors simply due to the fact that they are in different 
ranges. Normalization was done by linear scaling of the range of 
the values as follows:
 f x x x
x x
( ) min( )





The interaction values between cytokine pairs (ii) were cal-
culated in the following way: first calculating the product of the 
corresponding normalized cytokine values (i). Since the product 
of two uniform distributions ranging between 0 and 1 is a non-
uniform distribution, the second step was to apply a transforma-
tion that converts the non-uniform product distribution into a 
uniform distribution. The following equation was used for this 
transformation:
 f x x xln x( ) ( )= −  
This was derived in the following way: the distribution of the 
product of n uniformly distributed random variables on [0,1] 













1 . The desired transformation 
function is then precisely the integral of this probability density. 
Carrying out the integral for n = 2 gives the above transformation 
function.
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Ten-fold cross-validation (CV) with squared error loss was 
used to determine the shrinkage parameter λ. However, different 
realizations of the fold-split led to different CV errors and hence, 
mean CV error was obtained from 1,000 runs of CV to identify 
the optimal λ.
Predicted net effects are given as (i) the coefficient values of the 
regression model for individual cytokines and (ii) the sum of the 
individual cytokine coefficients and their interaction coefficient 
for cytokine pairs.
t-sne and Model-Based clustering
For t-SNE and clustering analysis, equivalent numbers of 
data points from three donors per condition were pooled. 
These samples were recorded using the same voltage settings 
on the flow cytometer. Fluorescence intensity values of each 
marker were normalized by linear scaling as described above 
for LASSO regression. t-SNE for dimensionality reduction 
(23) was performed using the Rtsne (24) R package and the 
following settings: maximum number of iterations =  10,000, 
perplexity = 258 (that is 10% of the total number of data points), 
theta = 0 (exact t-SNE).
Model-based clustering was performed using the flow-
Clust (25, 26) R package with the following settings: Gaussian 
mixture models were used (ν = ∞), convergence tolerance of 
expectation-maximization (EM) =  10−15, maximum number of 
EM iterations = 10 000, points outside 80% quantile region were 
considered as outliers (out of cluster). The number of clusters 
was chosen so that (i) the value of Bayesian information crite-
rion was close to zero and at the same time (ii) the number of 
clusters was minimal.
ethics statement
Peripheral blood mononuclear cells were freshly isolated from 
anonymized healthy donor buffy coats purchased from the 
Karolinska University Hospital (Karolinska Universitetssjukhuset, 
Huddinge), Sweden. Research was performed according to the 
national Swedish ethical regulations (ethical review act, SFS 
number 2003:460).
resUlTs
induction of gM-csF+ cD4+ T cells is 
Promoted by TgF-β and inhibited by il-6 
and il-23
To investigate conditions for induction of GM-CSF+ cells, 
we cultured human naïve CD4+ T cells in the presence of (i) 
IL-6, IL-21, and TGF-β1 that have been shown to be involved 
in the induction of IL-17+ cells (27–29), (ii) IL-1β, IL-23, and 
TGF-β3 that have been proposed to induce murine “patho-
genic” GM-CSF+IL-17+ cells (11, 14–16), and (iii) IL-2 that 
has been reported to induce human GM-CSF+ CD4+ T cells 
(5, 9). Along with these cytokines, the cells were activated 
with anti-CD3-, anti-CD28-coated beads (anti-CD3/CD28 
beads) for 5–6 days, and GM-CSF expression was measured by 
intracellular flow cytometry. We cultured the cells in serum-
free X-VIVO 15 medium with, if not otherwise stated, a final 
sodium concentration of 145.8 mM, which we consider “physi-
ologic” sodium levels similar to the concentration in blood 
(135–145 mM). As demonstrated by others before, addition of 
10–40 mM NaCl to X-VIVO 15 medium is  suitable for differen-
tiation cultures of human CD4+ T cells and is equivalent to the 
concentrations found in the interstitium of mice on high-salt 
diet (18, 19, 30). Importantly, these increased NaCl concentra-
tions were required to detect substantial fractions of Th17 cells, 
and the authors demonstrated that osmolarity was not causing 
this effect but specifically sodium was responsible for induc-
ing “pathogenic” Th17 cells (13, 18). We chose to add 30  mM 
NaCl (145.8 mM final sodium) in our experiments to represent 
conditions allowing for Th17 induction and at the same time 
maintaining high cell viability (as measured by flow cytometry; 
data not shown) and physiological sodium concentrations.
Under these conditions, we found that the induction of 
GM-CSF+ cells was enhanced by TGF-β and was inhibited by 
pro-inflammatory cytokines, in particular by IL-6 and IL-23 
(Figure  1). The anti-inflammatory cytokine IL-10 did neither 
markedly increase nor decrease GM-CSF expression. TGF-β1 
and TGF-β3 had similar effects on GM-CSF induction, and we 
therefore further focused our investigations on TGF-β1 because 
this is the most abundant isoform throughout the human body 
(31). TGF-β1 increased the secretion of GM-CSF in cell culture 
supernatants, as measured by ELISA (Figure 2A). In unstimu-
lated naïve CD4+ T cells, GM-CSF was detectable neither in the 
supernatant nor in PMA/Iono/BFA-pulsed or un-pulsed cells 
in flow cytometry (data not shown). When assaying GM-CSF 
expression at different time points of activation, we confirmed 
that TGF-β1 significantly enhanced the fraction of GM-CSF+ 
cells (Figures 2B,C). Taken together, these data demonstrate that 
TGF-β can increase GM-CSF expression in differentiating human 
CD4+ T cells.
The gM-csF-inducing effect of TgF-β is 
independent of il-2 signaling and 
Proliferation
IL-2 is abundantly produced by activated CD4+ T cells, and it has 
been proposed that IL-2 is capable to induce GM-CSF expression 
in differentiating human CD4+ T cells (5, 9). Therefore, we con-
sidered the possibility that TGF-β may enhance IL-2 expression 
or IL-2 responsiveness, which in turn might induce the expres-
sion of GM-CSF. To inspect this possibility, we either added 
IL-2 to the culture or neutralized secreted IL-2 with a blocking 
antibody. Addition of IL-2 did not increase GM-CSF+ cell frac-
tions (Figures  2D,E). Importantly, TGF-β1 had an enhancing 
effect on GM-CSF cell fractions also in the presence of IL-2 
(Figures 2D,E). Furthermore, neutralization of IL-2 in the super-
natant had no effect on TGF-β1-induced GM-CSF expression; 
however, this method of IL-2 blocking did not affect proliferation 
despite use of previously published (5) or higher concentrations 
of blocking antibody (Figure S1 in Supplementary Material and 
data not shown). Furthermore, we used a STAT5 inhibitor and 
observed that STAT5 inhibition did not prevent GM-CSF induc-
tion by TGF-β, corroborating that TGF-β-induced expression of 
GM-CSF is independent of IL-2 signaling (Figures 3A,B). At the 
FigUre 1 | capability of different cytokines to induce human gM-csF+ cD4+ T cells. Human naïve CD4+ T cells were activated with anti-CD3/CD28 beads 
in the presence of the indicated cytokines for 5–6 days. The percentage of GM-CSF+ cells within live CD4+ T cells was measured by intracellular flow cytometry after 
5 h of restimulation with phorbol 12-myristate 13-acetate (PMA) and Ionomycin in the presence of Brefeldin A (PMA/Iono/BFA). Bars represent mean + SEM of 2–15 
donors. The lower panel represents cytokine concentrations (white: absence of cytokine; gray to black: low to high concentrations with the concentrations and units 
given on the right side of the table). The bar highlighted in red represents the reference, that is, stimulation with anti-CD3/CD28 in medium without cytokine addition 
(No cytokine).
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same time as expected, STAT5 inhibition reduced proliferation 
since proliferation is enhanced by IL-2 signaling (Figure 3C).
Since we observed that GM-CSF expression was higher in 
proliferating cells, we investigated whether TGF-β1 increased the 
percentage of GM-CSF+ cells merely by increasing their prolifera-
tion. Therefore, we compared the percentage of GM-CSF+ cells 
within each proliferation cycle thereby conditioning on prolifera-
tion and eliminating its possibly confounding effects. Compared 
to activation without TGF-β1, TGF-β1 induced higher fractions 
of GM-CSF+ cells in every proliferation cycle (and in the presence 
of STAT5 inhibitor), suggesting that this effect is independent 
of proliferation (Figures  3A,B). Together, our data show that 
GM-CSF expression is enhanced by TGF-β independently of the 
proliferation state and IL-2 signaling.
TgF-β-induced gM-csF expression is 
Dependent on the Mode of T cell 
activation
Because TGF-β has been shown to have no or inhibitory effects 
on GM-CSF expression in other studies (5, 9), we asked whether 
the activation conditions could affect the TGF-β-mediated 
effect on GM-CSF. In our experiments showing augmentation 
of GM-CSF expression by TGF-β, we used stimulation with 
bead-bound anti-CD3/CD28 antibodies, which induced robust 
proliferation of T cells (Figures 3). When we used pb anti-CD3 
plus soluble anti-CD28 antibodies instead, this stimulation failed 
to induce robust proliferation of the cells but instead prolifera-
tion required external addition of IL-2 (Figure 4A). Under these 
FigUre 2 | TgF-β enhances and il-2 does not affect the differentiation of gM-csF+ cD4+ T cells. Human naïve CD4+ T cells were activated with anti-CD3/
CD28 beads in the presence of the indicated cytokines for 4–6 days. GM-CSF expression was either measured in the supernatant or cells were restimulated with 
PMA/Iono/BFA, and the percentage of GM-CSF+ cells within live CD4+ T cells was measured by intracellular flow cytometry. (a) After stimulation for 5 days, levels of 
secreted GM-CSF in the cell culture supernatant from cells activated in the absence (No cytokine) or presence of TGF-β1 (TGF-β1) were measured by ELISA. 
Replicate well cell platings were measured separately, ELISA readings for replicate wells were averaged and dots show the mean values. Each line represents a 
single donor. (B) The percentage of GM-CSF+ cells among live CD4+ T cells is shown comparing activation (No cytokine) and activation in the presence of TGF-β1 
(TGF-β1) for the indicated time periods. Each line represents a single donor. (c) As an example for a donor from (B), flow cytometry contour plots of the following 
samples gated on live cells are shown from one donor after 6 days of stimulation: isotype control for GM-CSF (Isotype), fluorescence-minus-one control for GM-CSF 
(FMO GM-CSF), activation alone (No cytokine), activation in the presence of TGF-β1 (TGF-β1). (D) The percentage of GM-CSF+ cells among live CD4+ T cells is 
shown comparing the effects of activation in the presence of IL-2 (IL-2), activation alone (No cytokine), and activation in the presence of IL-2 and TGF-β1 (IL-
2 + TGF-β1). Each line represents a single donor; symbols as in (B). (e) As an example for (D), flow cytometry contour plots of the following samples gated on live 
cells are shown from one donor after 6 days of stimulation: activation in the presence of IL-2 (IL-2), activation in the presence of IL-2 and TGF-β1 (IL-2 + TGF-β1). 
Statistical significance was calculated using non-parametric paired Wilcoxon signed-rank test (p-values are indicated).
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FigUre 3 | induction of human gM-csF+ cD4+ T cells by TgF-β is independent of sTaT5 and proliferation. Human naïve CD4+ T cells were labeled using 
Cell Proliferation Dye eFluor450 and were activated with anti-CD3/CD28 beads alone (No cytokine), in the presence of TGF-β1 (TGF-β1) or in the presence of 
TGF-β1 plus STAT5 inhibitor (TGF-β1 + STAT5i) for 4 days. The percentage of GM-CSF+ cells within live CD4+ T cells within each cycle was measured by intracellular 
flow cytometry after restimulation with PMA/Iono/BFA. (a) Representative dot plots for each stimulation condition. (B) Percentage of GM-CSF+ cells within the given 
proliferation cycles is shown for each stimulation condition [as labeled in (a)]. Each line represents a single donor. (c) Distribution of cell populations across 
proliferation cycles is shown for each stimulation condition as in (a). Each line represents a single donor.
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FigUre 4 | The effect of TgF-β on the differentiation of human gM-csF+ cD4+ T cells is dependent on the type of activation. Human naïve CD4+ T cells 
were labeled using Cell Proliferation Dye eFluor450 and were activated with pb anti-CD3 and soluble anti-CD28 antibodies alone (No cytokine), in the presence of 
IL-2 (IL-2) or in the presence of IL-2 plus TGF-β1 (IL-2 + TGF-β1) for 6 days. (a) Dot plots showing proliferation in the absence (No cytokine) or presence of IL-2 
(IL-2). Data from an example donor are shown. (B) The percentage of GM-CSF+ cells within live, blasted CD4+ T cells was measured by intracellular flow cytometry 
after restimulation with PMA/Iono/BFA, comparing the effects of IL-2 alone (IL-2) and IL-2 plus TGF-β1 (IL-2 + TGF-β1). Each line represents a single donor. 
Statistical significance was calculated using non-parametric paired Wilcoxon signed-rank test (p-values are indicated).
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conditions of pb anti-CD3 and soluble anti-CD28 stimulation 
plus IL-2, we observed that TGF-β reduced GM-CSF+ cell frac-
tions (Figure 4B), suggesting that the GM-CSF-enhancing effect 
of TGF-β is dependent on the mode of T cell activation.
TgF-β-induced gM-csF expression is 
Dependent on the sodium concentration
As described above, we cultured T cells under “physiologic” 
sodium conditions (145.8  mM total sodium) representing 
slight hypernatremia compared to blood but levels reasonable 
in interstitium. To compare with “low sodium” conditions, 
we cultured cells as above with anti-CD3/CD28 beads with or 
without TGF-β1 but without addition of sodium chloride, that 
is at 115.8  mM sodium final concentration. Interestingly, the 
TGF-β effect that induced GM-CSF under “physiologic” sodium 
concentrations was reversed in these “low sodium” experiments: 
under low sodium conditions, TGF-β reduced GM-CSF expres-
sion regarding the total amount of secreted GM-CSF (Figure 5A) 
as well as regarding the fraction of GM-CSF+ cells (Figure 5B), 
which was the reverse effect of TGF-β1 as compared to the effect 
under “physiologic” sodium levels (Figure 2) even when directly 
compared within the same donors (Figure 5B). In the absence 
of TGF-β, GM-CSF+ cell fractions were increased in low sodium 
compared to physiologic sodium concentrations (Figure  5B). 
The inhibitory effect of TGF-β1 on GM-CSF under low sodium 
conditions was independent of proliferation, as it was observed 
throughout multiple proliferation cycles (Figure  5C). Notably, 
we observed that TGF-β increased FOXP3 [a well-known effect 
(31)] irrespective of NaCl addition to the medium (Figure 5D). 
Correspondingly, a slight inhibition of IFN-γ by TGF-β, which 
is a known effect (32–34), seemed to occur under low sodium 
conditions; however in the presence of physiological sodium 
concentrations, the fractions of IFN-γ+ cells were generally much 
higher and an effect of TGF-β was not apparent (Figure  5E). 
Together, these results suggest that the effect of TGF-β specifically 
on GM-CSF expression is affected by sodium concentrations in 
the medium.
gM-csF has similar induction 
requirements as FOXP3 on the Population 
level
In previous studies, a fraction of GM-CSF+ cells has been found 
to co-express some other cytokines, but this has not been tested 
on single-cell level in all studies (5, 11, 13, 14, 18, 35). Single-
positive GM-CSF+ cells have been suggested to be a separate 
subset not expressing other T cell subset markers (5). The co-
expression of GM-CSF with other T cell markers has not been 
analyzed previously in an unbiased manner with computational 
tools. Therefore, to characterize which T cell subset markers are 
co-regulated with GM-CSF, we analyzed the correlations between 
pairs of GM-CSF+ cell fractions and cell fractions positive for 
CD25, IFN-γ, IL-17A, or FOXP3, respectively, under physiologic 
sodium concentrations and across several cytokine stimulation 
conditions (Figure 6A, cytokine conditions as in Figure 1). Across 
conditions, the CD25+ and FOXP3+ fractions were most strongly 
correlated with the GM-CSF+ fractions, followed by the IFN-γ+ 
and IL-17A+ fractions. This shows that on the population level, 
among the given set of “T cell subset” markers, FOXP3 is most 
co-regulated with GM-CSF throughout the cytokine stimulations 
applied. This suggests that GM-CSF and FOXP3 are induced by 
FigUre 5 | The effect of TgF-β on gM-csF induction is affected by the sodium concentration. Human naïve CD4+ T cells were activated with anti-CD3/
CD28 beads in the presence or absence of TGF-β1 for 5 days. A fraction of the supernatant was removed for ELISA, and then cells were restimulated with PMA/
Iono/BFA and GM-CSF, IFN-γ, and FOXP3 within live CD4+ T cells were measured. (a) Levels of secreted GM-CSF were measured by ELISA for cells cultured 
under low sodium conditions; data are displayed according to the description in Figure 2a. (B) The percentage of GM-CSF+ cells among live CD4+ T cells is 
shown comparing activation (No cytokine) and activation in the presence of TGF-β1 (TGF-β1) either under “physiologic” (phys.) or “low” sodium concentrations as 
indicated. Each line represents a single donor. (c) Human naïve CD4+ T cells (labeled with Cell Proliferation Dye eFluor450) were activated with anti-CD3/CD28 
beads alone (No cytokine) or in the presence of TGF-β1 (TGF-β1) under low sodium conditions for 5 days. The percentage of GM-CSF+ cells within live CD4+ 
T cells within each cycle was measured by intracellular flow cytometry after restimulation with PMA/Iono/BFA. The upper panels show flow cytometry raw data 
from one donor for both stimulation conditions, the lower panel shows the percentage of GM-CSF+ cells within the given proliferation cycles with lines colored 
according to donor and TGF-β1 addition indicated by dashed lines. (D) FOXP3+ and (e) IFN-γ+ cell fractions among live CD4+ T cells were determined and are 
presented as in (B).
9
Éliás et al. TGF-β Induces Human GM-CSF+ CD4+ T Cells
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 603




Éliás et al. TGF-β Induces Human GM-CSF+ CD4+ T Cells
Frontiers in Immunology | www.frontiersin.org December 2016 | Volume 7 | Article 603
similar cytokines and the well-known FOXP3-inducing effect of 
TGF-β (31) corresponds to our observation that TGF-β induces 
GM-CSF.
To rigorously identify the induction and repression require-
ments for GM-CSF, we applied LASSO regularized regression 
on our data where we considered the change in percentage of 
GM-CSF+ cells (compared to control cells activated without 
cytokine) as target variable and the normalized concentration of 
added cytokines as predictors (see Materials and Methods and 
Figure 1). Details of the model selection are provided in Figure S2 
in Supplementary Material. From this analysis, we discovered that 
TGF-β was primarily responsible for the induction of GM-CSF, 
and IL-6 and IL-23 for its repression (Figure 6B), thus confirming 
the patterns observed in Figure 1. We carried out the same analy-
sis for all the given markers, and for FOXP3 the inducing and 
repressing factors were very similar to those of GM-CSF, when we 
considered the change in the percentage of FOXP3+ cells as target 
variable (data not shown).
gM-csF is Most strongly co-expressed 
with iFn-γ on the single-cell level
The above analyses examined the correlation of GM-CSF with 
other markers at bulk cell population level across the inducing 
conditions, but that does not reveal to what extent any two markers 
are expressed by the same cell. Information about co-expression 
of other markers with GM-CSF on the single-cell level is however 
important considering the crucial role of GM-CSF+ T cells in 
EAE induction (6–8) and the unclear role of “pathogenic” Th17 
cells, particularly in the human system. High correlation between 
positive cell fractions defined based on a pair of markers across 
stimulation conditions does not necessarily imply that these 
markers are expressed by the very same cells. To find the marker 
most preferentially co-expressed by the same cells as GM-CSF, 
we calculated the Spearman correlations between pairs composed 
of GM-CSF and either FOXP3, CD25, IFN-γ, or IL-17A, across 
single cells, under the conditions given in Figure 1. To visualize 
our results and to account for potentially different results based 
on certain types of inducing cytokines, we divided the condi-
tions into subsets (defined in Figure  6C). We determined that 
across single cells it was IFN-γ that was most correlated with 
GM-CSF irrespective of the inducing cytokine condition, while 
FOXP3 was less correlated (Figure 6C). Importantly, even under 
Th17-inducing conditions, either with or without TGF-β, IL-17A 
had the lowest correlation with GM-CSF on single-cell level 
(Figure 6C). Together, these results demonstrate that among the 
set of markers that we investigated, GM-CSF is most preferentially 
produced by the same single cells as IFN-γ throughout a range of 
different cytokine conditions.
FigUre 6 | continued  
Human naïve CD4+ T cells were activated with anti-CD3/CD28 beads in the presence of the cytokines indicated in Figure 1 for 3–7 days. GM-CSF, IL-17A, IFN-γ, 
FOXP3, and CD25 within live CD4+ T cells were measured. (a) Correlation analysis based on the percentage positive cells for each marker across different 
stimulation conditions. Diagonal: markers considered in the analysis. Left to the diagonal: pairwise dot plots of markers showing percentage of positive cells across 
samples. Each sample is represented by a single dot and is defined by stimulation condition, donor, and experiment. Right to the diagonal: upper value denotes the 
Spearman correlation coefficient of percentage positive cells for the given pairs of markers, lower value denotes the p-value calculated using a paired t-test 
considering the Spearman correlation coefficient (ρ) as random variable and testing the null-hypothesis that it is zero (H0: ρ = 0). (B) The change in the GM-CSF+ cell 
fraction within live cells compared to the control (No cytokine) was considered as target variable and the normalized cytokine concentrations (including interaction 
effects) and time (3–7 days of activation) were considered as predictors in LASSO linear regression. Predicted net effects of cytokines and cytokine pairs on the 
change in the GM-CSF+ cell fraction compared to control are shown for the selected model. (c) Correlation analysis using normalized single-cell fluorescence 
intensity values of each marker. Samples were grouped based on stimulation condition, and the Spearman correlation between the indicated pairs of markers was 
calculated on the single-cell level and is shown as boxplot [samples as in (a)]. (a–c) Data from 2 to 15 donors per group were used. (D) Cells were stimulated with 
TGF-β1 (TGF-β1) or without (No cytokine). Pre-gated on live GM-CSF+ cells, t-SNE analysis of subpopulations (as specified in Figure S4 in Supplementary Material) 
followed by model-based clustering was performed. Data from three donors per group was pooled.
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To confirm these results in a completely independent study 
and at the same time on mRNA level in murine in vivo generated 
cells, we analyzed publicly available single-cell RNA-sequencing 
data from Th17 cells published by Regev and colleagues (36). Here, 
IL-17A+ cells were sorted (based on GFP reporter expression) from 
mice at the peak of EAE disease from the central nervous system 
(CNS) and lymph nodes (LN), respectively. Using the data from 
these single sorted Th17 cells, we analyzed on the single-cell level 
the correlation of expression of the gene encoding for GM-CSF 
(Csf2) with the genes encoding for the markers (IFN-γ, FOXP3, 
IL-17, CD25) that we studied in human cells before. Notably, 
despite being sorted based on IL-17A expression, the single cells 
displayed a range of Il17a and Il17f expression including non-
expressing cells, which allowed us to analyze the correlation of 
Csf2 also with Il17a and Il17f (Figures S3A,B in Supplementary 
Material). Csf2 expression in CNS-derived Th17 cells was strongly 
FigUre 7 | Quantification of cell population subsets throughout differentiation phases represented by cumulative number of cell cycles. Human naïve 
CD4+ T cells were labeled using Cell Proliferation Dye eFluor450 and were activated with anti-CD3/CD28 beads alone (No cytokine) or in the presence of “TGF-β1” 
for 6 days. The percentage of given subpopulations within live CD4+ T cells and within each cycle was measured by intracellular flow cytometry after restimulation 
with PMA/Iono/BFA. (a) Representative dot plots for each stimulation condition. (B,c) Percentage of cells in all quadrants using the GM-CSF and FOXP3 marker 
pair (B) or GM-CSF and IFN-γ marker pair (c) within each cycle are given. In addition, triple-positive cells for GM-CSF, IFN-γ, and FOXP3 are indicated in red in 
(B,c). Data are presented as mean + SEM of six donors.
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correlated with Ifng and Il2ra, corresponding to our results from 
in vitro generated human cells, whereas Foxp3, Il17a, and Il17f 
were not correlated with Csf2 (Figure S3A in Supplementary 
Material). LN-derived Th17 cells exhibited a different pattern, 
with Csf2 correlating with Il17a, Il17f, and Il2ra but not Ifng  
(Figure S3B in Supplementary Material).
gM-csF+ cD4+ T cells comprise several 
subpopulations
The above data show that despite the presence of “GM-CSF 
only” single-positive cells (with respect to the markers studied 
herein), GM-CSF+ CD4+ T cells co-express a range of different 
other “subset-specific” CD4+ T cell markers. To gain insight to the 
heterogeneity and possible subpopulation structure of GM-CSF+ 
CD4+ T cells, we performed an unbiased computational analysis 
using t-SNE (23), a non-linear dimensionality reduction tech-
nique, followed by model-based clustering of single cells. First, 
we selected GM-CSF+ cells separately from both induction 
conditions (with or without TGF-β). Next, the multi-dimensional 
data containing intensity values of all other measured markers 
(except GM-CSF) was projected to two dimensions using t-SNE, 
and in the two-dimensional space cells were clustered using 
model-based clustering. In detail, we pre-gated on GM-CSF+ 
cells and studied their subpopulations based on expression levels 
of five other markers (FOXP3, CD25, IFN-γ, cell proliferation 
dye, IL-2). We determined that GM-CSF+ cells clearly comprised 
several subpopulations with different combinations of expression 
of the other markers (Figure  6D; Figure S4 in Supplementary 
Material). Furthermore, the subpopulations within GM-CSF+ 
CD4+ T cells induced by activation only (No cytokine) were 
clearly distinct with bimodal expression of the measured mark-
ers. However, subpopulations within GM-CSF+ CD4+ T cells 
induced by activation plus TGF-β appeared more connected, with 
a corresponding graded expression of FOXP3 (Figure 6D; Figure 
S4 in Supplementary Material). Taken together, the above data 
show that GM-CSF+ CD4+ T cells comprise several subpopula-
tions co-expressing other T cell subset markers on the single-cell 
level. Of these, IFN-γ was most strongly correlated with GM-CSF 
independent of the condition, and TGF-β increased the fraction 
of GM-CSF+ cells co-expressing FOXP3.
cell Population composition changes 
throughout the Time course of 
Differentiation
As described above, FOXP3 as well as IFN-γ harbored the 
strongest correlation with GM-CSF expression. To extract 
information about plausible trajectories of the differentiation 
of GM-CSF+ CD4+ T cells, we used labeling with a proliferation 
dye to track the number of cumulative cycles in each cell and 
used it as an approximation of the differentiation phase based on 
the assumption that more activated and differentiated cells have 
gone through more rounds of cell cycle. In each generation, we 
investigated the composition of the population with respect to the 
fractions in each quadrant defined by the FOXP3/GM-CSF and 
IFN-γ/GM-CSF pairs. We carried out this analysis separately on 
samples that were activated without any cytokine and samples 
that were activated in the presence of TGF-β1, since we observed 
that although the GM-CSF+ fraction was increased by TGF-β, 
in both conditions there were GM-CSF+ cells and they might 
represent different types of GM-CSF+ cells.
We determined that in both conditions only the double-
negative fractions of IFN-γ−GM-CSF− and FOXP3−GM-CSF− 
decreased monotonously over generations, showing that the 
averaged expression of these markers increases as cells proliferate 
in both conditions (Figure 7). Interestingly, in the presence of 
TGF-β1, the FOXP3+GM-CSF+ fraction monotonously increased 
over generations whereas the FOXP3+GM-CSF− fraction showed 
a unique distribution curve over the generations with an increase 
up to cycle 2 and decrease from cycle 2 to 5 (Figure 7B). Without 
TGF-β1 instead, the fraction of FOXP3+ cells was generally low 
but still, the shape of the population curves over generations was 
similar as without TGF-β1 (Figure  7B). The fractions positive 
for any combination of IFN-γ and GM-CSF generally increased 
over generations (Figure 7C). Taken together, these analyses sug-
gest that expression of GM-CSF and IFN-γ occurs with similar 
kinetics, while FOXP3+ cells appear earlier than GM-CSF+ cells. 
Notably, also cells triple-positive for GM-CSF, IFN-γ, and FOXP3 
were observed (Figures 7B,C), the fraction of which was low in 
the early cycles and increased in later stages, reaching a substan-
tial fraction upon addition of TGF-β.
DiscUssiOn
The main finding of this study is that TGF-β can enhance GM-CSF 
induction during human CD4+ T cell differentiation, and these 
GM-CSF+ CD4+ T cells comprise several subpopulations that 
co-express other T cell subset markers such as IFN-γ or FOXP3. 
Besides TGF-β, we have screened a range of cytokines and their 
combinations for their ability to induce GM-CSF. To our knowl-
edge, the present study is the largest comparative study concern-
ing GM-CSF-inducing conditions in human CD4+ T cells and 
the first example of employing a data-driven, unbiased analysis 
of GM-CSF-inducing conditions, GM-CSF+ cell subpopulation 
composition as well as correlation of GM-CSF with other mark-
ers. This study advances our understanding of the complexity of 
human GM-CSF+ CD4+ T cell induction and phenotype.
Illustrating the complexity of the differentiation of these cells, 
we also discovered that the effect of TGF-β on human GM-CSF+ 
CD4+ T cell differentiation was dependent on the type of TCR 
activation and co-stimulation. Specifically, with anti-CD3/CD28 
bead-mediated T cell activation TGF-β enhanced GM-CSF+ 
CD4+ T cell differentiation, whereas upon pb anti-CD3 and 
soluble anti-CD28-mediated T cell activation TGF-β repressed 
GM-CSF. In our experiments, activation by anti-CD3/CD28 
beads induced more T cell proliferation than the activation by 
pb anti-CD3 and soluble anti-CD28 antibodies. Nevertheless, 
the activation-dependent differential effect of TGF-β on human 
GM-CSF+ CD4+ T cell differentiation was not due to different 
extent of proliferation, because the TGF-β effect was observed 
in each cycle when conditioning on the number of cumulative 
cell cycles. The differential effect of TGF-β on GM-CSF induction 
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between the two activation types may be due to differences in 
the strength of activation, difference in the ratio of anti-CD3 and 
anti-CD28 antibodies and/or differences in the basal GM-CSF 
expression without addition of cytokines. Our findings identify 
a novel, context-dependent role of TGF-β in the regulation of 
human CD4+ T cell differentiation.
Previous studies investigating the effect of TGF-β on human 
GM-CSF+ CD4+ T cell differentiation have reported either 
neutral (5) or inhibitory (9) effects, and those differences may be 
related to the experimental settings such as mode of T cell activa-
tion which, based on our data, may change GM-CSF induction. 
In both of these studies, the authors used 10 ng/ml TGF-β, pb 
anti-CD3-, and soluble anti-CD28-mediated T cell activation at 
similar concentrations and slightly different markers for defining 
and sorting human naïve CD4+ T cells. The cell culture medium 
may also influence T cell differentiation. While we used serum-
free X-VIVO 15 medium, Zielinski and colleagues (5) used RPMI 
1640 medium supplemented with 5% human serum and they 
observed that TGF-β had no effect on human GM-CSF+ CD4+ 
T cell differentiation (5). Because serum contains high levels of 
TGF-β that may be biologically active (37, 38), and bovine serum-
derived TGF-β1 is 100% conserved compared to the human 
TGF-β1 protein, this might have precluded the possibility for the 
authors to study potential effects of exogenously added TGF-β 
(5). In the abovementioned study that described inhibitory effects 
of TGF-β on human GM-CSF+ CD4+ T cell induction, the authors 
did not specify which medium and whether serum was used (9). 
Importantly, our results also show that the GM-CSF induction 
upon TGF-β was influenced by the sodium concentration in 
the medium, which is affected by addition of serum and differs 
between X-VIVO 15 medium and RPMI 1640 medium (the latter 
containing 133 mM sodium). Further, IFN-γ+ cell fractions were 
generally higher with physiological compared to low sodium 
concentration within the range we tested. Because sodium has 
been suggested to drive “pathogenic” Th17 differentiation in 
EAE models, and pathogenic cells in EAE have been associated 
with GM-CSF and IFN-γ expression (6–8, 13, 18), we consider 
it important to study GM-CSF induction under “physiologic” 
sodium concentrations and to our knowledge, we are the first 
to study effects of sodium on GM-CSF induction without Th17-
inducing cytokine conditions. To our knowledge, there is also no 
study that investigated the effect of TGF-β on GM-CSF+ T cell 
differentiation from human naïve CD4+ T cells in the presence 
of anti-CD3/CD28 beads, although T cell stimulation with such 
beads is similar to physiological activation because it mimics the 
interaction with antigen-presenting cells (39, 40).
It has further been suggested from studies in mice that 
TGF-β1 and TGF-β3 have differential effects, TGF-β3 induc-
ing “pathogenic” GM-CSF+IL-17+ cells and TGF-β1 inducing 
GM-CSF−IL-17+ cells. Mechanistically, it was proposed that NaCl 
activates the kinase SGK1 that in turn increases IL-23R expression, 
consequently through IL-23R signaling enhancing the secretion 
of TGF-β3 which confers pathogenic properties to IL-17+ cells, 
including GM-CSF production (11, 13, 18). Contradicting this 
notion however, T cells from either Il23r−/− or Sgk1−/− mice cul-
tured under Th17-polarizing conditions expressed increased Csf2 
levels compared to the wild-type counterpart (13), leaving the 
mechanism of sodium effects on GM-CSF unclear to date. Our 
data do not provide any evidence that TGF-β1 and TGF-β3 have 
differential qualitative effects on human GM-CSF expression, or 
any of the other markers we measured. This is in accordance with 
another study showing that TGF-β1 and TGF-β3 have similar 
effects on human GM-CSF+ CD4+ T cells (9), even though a dif-
ferent mode of T cell activation was applied here. Importantly, 
we did not observe an increased occurrence of GM-CSF+IL-17A+ 
cells in the presence of TGF-β3. Together, these data suggest that 
in contrast to the proposed mechanisms in the murine system 
(11), TGF-β3 does not seem to have a role in inducing specifically 
“pathogenic” human GM-CSF-producing (Th17) cells and did not 
affect human cells differentially as compared to TGF-β1. Another 
study performed in mice found that – also in the presence of IL-6 
but with antigen-specific stimulation in contrast to Ref (11) – both 
TGF-β1 and TGF-β3 were unable to induce “pathogenic” murine 
Th17 cells, whereas myelin-specific Th1 cells and pathogenic Th17 
cells – differentiated in the absence of TGF-β – produced GM-CSF 
as measured on the bulk population level (17). It remains to be 
determined whether GM-CSF+IFN-γ+ double-positive cells are 
driving the pathogenesis of murine EAE, and whether there are 
differences in the murine versus human system, although the 
latter is difficult to assess due to the impossibility of functional 
“pathogenicity” assays in humans.
IL-2 has been reported to enhance the differentiation of 
human GM-CSF+ CD4+ T cells independently of proliferation 
since the increased percentage of GM-CSF+ cells as a function of 
IL-2 concentration was present in every proliferation generation 
(5, 9). Since IL-2 is abundantly produced by T cells and also 
required for T cell activation and proliferation, it is difficult 
to study how the absence of IL-2 affects differentiation. In our 
experiments, the absence of exogenous IL-2 or blocking of IL-2 
by neutralizing antibodies drastically reduced T cell proliferation 
when human naïve CD4+ T cells were activated by pb anti-CD3 
and soluble anti-CD28 antibodies, but not when they were 
activated by anti-CD3/CD28 beads. The latter generally led to 
stronger activation, as assessed by CD25 upregulation and prolif-
eration. This suggests that with bead stimulation the amount of 
endogenously produced IL-2 can overcome the lack of exogenous 
IL-2 supplementation and renders IL-2 neutralization insufficient. 
This possibility is consistent with our observation that addition of 
IL-2 in the presence of anti-CD3/CD28 bead-mediated activation 
affected neither the expression of GM-CSF nor the other mark-
ers we measured including proliferation. When we blocked IL-2 
signaling by a pharmacological inhibitor of STAT5, proliferation 
was decreased indicating that IL-2 signaling was blocked, never-
theless GM-CSF+ fractions within in each proliferation cycle were 
unchanged suggesting that TGF-β enhances GM-CSF expression 
in cells activated by anti-CD3/CD28 beads independently of IL-2 
signaling. Although GM-CSF+ production was generally higher 
in cells that underwent more proliferation cycles, the effect of 
different cytokines on GM-CSF expression was yet independent 
of proliferation, consistent with the results of previous studies on 
human GM-CSF+ cells (5, 9).
IL-7 and IL-21 belong to the same cytokine family as IL-2, 
and IL-7 has been suggested from mouse and human studies as 
an inducing cytokine of GM-CSF+ CD4+ T cells (9, 41). In the 
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same way as IL-2, neither IL-7 nor IL-21 enhanced GM-CSF 
induction in our experiments with bead-bound anti-CD3/CD28 
stimulation. This indicates that signaling via the common gamma 
chain cytokine receptor – which involves STAT5 – might gener-
ally affect GM-CSF expression differentially in an activation-type 
dependent manner.
IL-12 – that is known as a Th1-inducing cytokine – has been 
suggested from studies both in murine and human cells to induce 
GM-CSF+ CD4+ T cells (5, 17, 42). In our experiments with bead 
stimulation, IL-12 had no effect on GM-CSF induction but it 
increased IFN-γ expression as expected (data not shown), again 
highlighting the sensitivity of GM-CSF induction to differences in 
experimental conditions. Other IL-12 family members are IL-23 
(that augments Th17 responses as described above) and IL-27 [that 
drives anti-inflammatory IL-10 responses (43)]. IL-27 has been 
demonstrated to inhibit GM-CSF production by both murine and 
human cells (5, 44). In our experiments, the anti-inflammatory 
cytokine IL-10, belonging to a different family of cytokines, did 
not have notable effects on GM-CSF expression.
Th17-driving cytokines such as IL-1β and IL-23 enhanced 
GM-CSF+ cell fractions in murine cells, and it was suggested that 
GM-CSF is co-produced with IL-17 (14). In our experiments 
(in the presence of bead activation), IL-1β had a weak induc-
ing effect but IL-23 had a strong inhibitory effect on GM-CSF 
expression. This is in accordance with other studies on human 
cells using pb TCR activation (5, 9), suggesting that this effect – as 
opposed to the dual role of TGF-β in GM-CSF induction – is 
independent of the T cell activation mode, but might instead 
reflect differences between human and murine cells. Alternatively, 
the differences between mouse and human cells may be due to the 
tissue source: human T cells for in vitro culture studies are typi-
cally isolated from blood whereas murine T cells are commonly 
isolated from the spleen. Furthermore, it has to be considered 
that the in vitro activation and cytokine treatment of cells might 
not reflect the in  vivo priming situation and in addition, cells 
might be changed by the environment at the inflammatory site, 
such as in the brain in the case of MS. Furthermore, we found 
that IL-6 (another Th17-inducing cytokine) had a strong inhibi-
tory effect on GM-CSF expression, which is in agreement with 
a study inducing GM-CSF+ cells using pb CD3/CD28 activation 
(5) while in another study using such activation IL-6 had no effect 
(9). Overall, from our and other studies it appears that the dif-
ferentiation requirements of human IL-17+ and GM-CSF+ CD4+ 
T cells are different and the only “Th17-inducing” factor that did 
not exert opposing effects for the two subsets was IL-1β, which 
interestingly is required for IL-17 induction specifically in human 
T cells (45–48). For therapeutic approaches and interpretation 
of murine disease models, particularly for MS, it will be highly 
relevant to further understand the differences in the differentia-
tion requirements of murine and human IL-17+ and GM-CSF+ 
CD4+ T cells in the future.
To disentangle the relationship of GM-CSF with other major 
CD4+ T cell lineage markers, we systematically investigated 
the relationship between these in terms of their induction and 
repression requirements and their single-cell co-expression 
under several different cytokine conditions. From correlation 
and LASSO regularized regression analyses on the population 
level, it was apparent that GM-CSF had similar induction and 
repression requirements as FOXP3. However, when we inves-
tigated the correlation of GM-CSF and other markers in terms 
of their expression on the single-cell level, it was apparent that 
GM-CSF and IFN-γ were more co-expressed by the same cells 
than any other GM-CSF/marker pair that we studied. The co-
expression relationship between GM-CSF and IFN-γ in our data 
was very robust across different cytokine stimulation conditions 
suggesting that possibly GM-CSF and IFN-γ have a shared 
intracellular regulation, possibly common transcription factors 
regulating them. Furthermore, the results suggest that GM-CSF 
and FOXP3 have similar inducing and inhibiting factors on the 
population level, but they are regulated rather independently 
within a single cell. While we observed a correlation of GM-CSF 
and FOXP3 on the population as well as single-cell level in the 
human system, such correlation was not found in our analysis 
of murine single-cell Th17 data (36), which might reflect species 
differences concerning activation-induced FOXP3 expression 
in human conventional T cells or be a result of the inhibitory 
effects of RORγt on FOXP3 in Th17 cells. Regarding IFN-γ and 
GM-CSF, our analysis of this independent murine single-cell 
RNA-sequencing dataset (36) suggests that the co-expression of 
IFN-γ and GM-CSF in the same cell is a feature that is true across 
species, and it might specifically signify potentially pathogenic 
cells derived from the CNS. At least considering the subset of 
IL-17A+ cells, our analysis further suggests that co-expression 
patterns of GM-CSF with other markers differ depending on the 
tissue. Notably, most IL-17A+ murine T cells did not co-express 
Il17a and Csf2, whether derived from LN or CNS (36). However, 
in human brain lesions from MS patients substantial fractions 
of GM-CSF+IL-17A+ and GM-CSF+IFN-γ+ T cells were detected 
using immunohistochemistry (49). Interestingly, a recent study 
in which Hafler and colleagues cloned single myelin-reactive T 
cells from MS patients and healthy donors also determined that 
many IFN-γ+ clones also produced GM-CSF, and most IL-17-
producing clones from MS patients co-expressed GM-CSF – yet 
many T cell clones derived from MS patients that produced high 
levels of GM-CSF expressed neither IFN-γ nor IL-17 (10).
To characterize the possibly different subtypes of GM-CSF+ 
cells, we analyzed subpopulations of GM-CSF+ cells that were 
induced by activation only or by activation plus TGF-β applying 
t-SNE followed by model-based clustering. t-SNE revealed that 
GM-CSF+ cells induced by activation only had rather distinct 
groups as compared to GM-CSF+ cells induced with TGF-β. 
The different groups in the “No cytokine” condition had distinct 
levels of FOXP3, CD25, and IFN-γ, whereas the different groups 
in the “TGF-β” condition had graded levels of FOXP3 and CD25 
expression, but IFN-γ was still bimodally distributed across the 
clusters. This suggests that in the presence of TGF-β, when FOXP3 
is strongly induced, GM-CSF+ cells with slightly different FOXP3 
levels are distinct based on other markers, whereas without TGF-
β, FOXP3+GM-CSF+ cells are generally less frequent and form a 
distinct category. Interestingly, only when TGF-β was present, a 
rare population of FOXP3highCD25high cells that did not produce 
IL-2 was observed, which might represent a population of Treg-
like cells producing GM-CSF. Although these in vitro generated 
cells may be distinct from the situation in vivo, it is notable that 
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murine in vitro-induced Tregs were demonstrated to produce IFN-
γ and GM-CSF upon restimulation. However, these myelin auto-
antigen-specific Tregs did not induce EAE but instead suppressed 
pathology in  vivo, accompanied by loss of GM-CSF expression 
under inflammatory conditions (50). Interestingly, IL-6, IL-27, or 
a combination of IL-2 with TGF-β mediated this loss of GM-CSF 
expression in murine Tregs. Based on these results, it is tempting 
to speculate that GM-CSF+FOXP3+ cells might be a subset of Treg-
like cells, or alternatively they might reflect activation-induced 
FOXP3 expression in human cells (51, 52).
We and others have extensively studied the immune-suppres-
sive function of human in vitro TGF-β-induced FOXP3+ Treg cells 
(iTregs) (53), with conflicting results possibly due to differences 
in experimental setup during Treg induction or setup and con-
trols used in suppression assays (34, 54, 55). Activation-induced 
low and transient FOXP3 expression in human activated conven-
tional T cells further complicates such studies, which however 
mostly concur in the conclusion that (low) FOXP3 expression 
is insufficient to confer suppressive function. In a setup similar 
to the studies in the present work, we determined that despite 
high FOXP3 expression, iTreg suppressive function in vitro did 
not exceed unspecific “suppression” of FOXP3-negative control 
stimulated cells, except when iTregs were induced in the presence 
of TGF-β + retinoic acid + rapamycin (34). Nevertheless these 
TGF-β +  retinoic acid +  rapamycin iTregs did not suppress in 
a, though artificial, xenogeneic in  vivo suppression assay (34), 
highlighting the complexity of assays for determining iTreg 
suppressive function. A major complication with assays using 
human iTregs is that these cells lack epigenetic demethylation in 
the so-called Treg-specific demethylated region (TSDR) in the 
FOXP3 locus (56, 57) and hence lose FOXP3 upon restimulation 
(34, 58). Therefore, it would be complicated to study whether 
GM-CSF+FOXP3+ cells would lose GM-CSF upon restimulation 
in analogy to the murine system in Ref. (50). It remains subject 
to future investigations to test whether the rare population of 
GM-CSF+FOXP3highCD25highIL-2neg cells that we observed under 
TGF-β addition represents a population of suppressive Treg-like 
cells producing GM-CSF, testing of which would require the defi-
nition of a unique surface marker (combination) of this popula-
tion to enable its sorting for functional assays. Interestingly, while 
TGF-β-induced FOXP3 in our study did not seem to be affected by 
sodium addition, it was previously shown that suppressive activity 
of Tregs is reduced in the presence of added sodium (X-VIVO 15 
medium + 5% human serum + 40 mM NaCl) and interestingly, 
these Tregs upregulated IFN-γ and GM-CSF on gene and secreted 
protein level (19). Interesting aspects to study in the future would 
be the subpopulation composition and cytokine requirements of 
GM-CSF+ cells induced from naïve T cells of patients with MS, as 
well as potential differences in functionality regarding Treg-like 
FOXP3+ subpopulations compared to healthy donors.
In order to explore possible differentiation trajectories of 
GM-CSF+ cells, we used proliferation tracking as an approxi-
mation of differentiation stage. Interestingly, FOXP3+GM-
CSF− cells preferentially occurred in the earlier cycles whereas 
in the later cycles, when these cells decayed, FOXP3+GM-CSF+ 
cells increased. This suggests that possibly the cells stimulated 
by TGF-β first express FOXP3 and then acquire the expression 
of GM-CSF. Interestingly, particularly in late stages and under 
addition of TGF-β, also cells expressing all the three markers 
GM-CSF, IFN-γ, and FOXP3 emerged, the functionality of which 
remains to be determined. Individual expression levels of these 
markers per cell likely affects the functional outcome and might 
add an additional layer of complexity. Unfortunately, a study 
(10) that described that a similar fraction of T cell clones derived 
from MS patients and healthy donors co-expressed IFN-γ and 
GM-CSF did not include FOXP3 as an additional marker, which 
would be an interesting subject of future investigation to identify 
the in  vivo occurrence and potential relevance of such triple-
positive cells.
Overall, our study identifies an activation- and sodium-
dependent role for TGF-β in the induction of human GM-CSF+ 
CD4+ T cells and highlights potential species differences and 
context dependencies of GM-CSF induction. Our integrative 
characterization of the human GM-CSF+ CD4+ T cell population 
by computational and experimental methods (59, 60) adds to our 
understanding of the complexity of this cell population. These 
results have important implications for emerging considera-
tions regarding outcomes of low- or high-salt (Western) diet in 
the context of autoimmune diseases such as MS (61), as well as 
for future therapies to block GM-CSF in MS patients, which is 
already in a phase I clinical trial (62).
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